Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydroxychloroquine in PPMS
NCT02913157Phase 2Completed
- Sponsor
- University of Calgary
- Start
- Nov 2016
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of hydroxychloroquine in primary progressive multiple sclerosis (PPMS), sponsored by University of Calgary. Primary endpoint: Timed 25-Foot Walk at 18 months. Started Nov 2016; status: completed.
02
Drugs
hydroxychloroquine
03
Conditions
primary progressive multiple sclerosis (PPMS)
Beyond the preview
Go deeper on NCT02913157.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02913157.